Current Infectious Disease Reports

, Volume 5, Issue 5, pp 379–386

Group A streptococcal sepsis

  • Dennis L. Stevens
Article

Abstract

The fulminant nature of group A streptococcal sepsis poses impressive challenges from diagnostic and therapeutic perspectives. Most patients are seen early in the course of infection by primary care providers or emergency department physicians and sent home, only to return in 12 to 24 hours with fully developed group A streptococcal sepsis. Early diagnosis is imperative, but the clinician must have a high index of suspicion. Often, the diagnosis is established only after aggressive interventional management has begun. This review emphasizes salient clinical features and provides general recommendations for critical care management.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    The Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993, 269:390–391.CrossRefGoogle Scholar
  2. 2.
    Schwartz B, Facklam RR, Brieman RF: Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990, 336:1167–1171.PubMedCrossRefGoogle Scholar
  3. 3.
    Cockerill FR, MacDonald KL, Thompson RL, et al.: An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997, 277:38–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Outbreak of group A streptococcal pneumonia among Marine Corps recruits--California, November 1-December 20, 2002. MMWR Morb Mortal Wkly Rep 2003, 52:106–109.Google Scholar
  5. 5.
    Chaussee MS, Liu J, Stevens DL, Ferretti JJ: Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996, 173:901–908.PubMedGoogle Scholar
  6. 6.
    Gamba MA, Martinelli M, Schaad HJ, et al.: Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997, 24:1118–1121.PubMedGoogle Scholar
  7. 7.
    Dipersio JR, File TM, Stevens DL, et al.: Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996, 22:490–495.PubMedGoogle Scholar
  8. 8.
    Ichiyama S, Nakashima K, Shimokata K, et al.: Transmission of Streptococcus pyogenes causing toxic shock-like syndrome among family members and confirmation by DNA macrorestriction analysis. J Infect Dis 1997, 175:7231–7236.Google Scholar
  9. 9.
    Gamba MA, Martinelli M, Schaad HJ, et al.: Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997, 24:1118–1121.PubMedGoogle Scholar
  10. 10.
    Dipersio JR, File TM, Stevens DL, et al.: Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996, 22:490–495.PubMedGoogle Scholar
  11. 11.
    Auerbach SB, Schwartz B, Williams D, et al.: Outbreak of invasive group A streptococcal infections in a nursing home. Lessons on prevention and control. Arch Intern Med 1992, 152:1017–1022.PubMedCrossRefGoogle Scholar
  12. 12.
    Hohenboken JJ, Anderson F, Kaplan EL: Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality. In Program & Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL. 1994:Abstract J189.Google Scholar
  13. 13.
    Nosocomial group A streptococcal infections associated with asymptomatic health-care workers--Maryland and California, 1997. MMWR Morb Mortal Wkly Rep 1999, 48:163–166.Google Scholar
  14. 14.
    Stevens DL, Tanner MH, Winship J, et al.: Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Eng J Med 1989, 321:1–7.CrossRefGoogle Scholar
  15. 15.
    Bisno AL, Stevens DL: Streptococcal infections in skin and soft tissues. N Engl J Med 1996, 334:240–245.PubMedCrossRefGoogle Scholar
  16. 16.
    Demers B, Simor AE, Vellend H, et al.: Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991. Clin Infect Dis 1993, 16:792–800.PubMedGoogle Scholar
  17. 17.
    Stegmayr B, Bjorck S, Holm S, et al.: Septic shock induced by group A streptococcal infections: clinical and therapeutic aspects. Scand J Infect Dis 1992, 24:589–597.PubMedGoogle Scholar
  18. 18.
    Kim KS, Kaplan EL: Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr 1985, 107:681–684.PubMedCrossRefGoogle Scholar
  19. 19.
    Gatanaduy AS, Kaplan EL, Huwe BB, et al.: Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980, 2:498–502.CrossRefGoogle Scholar
  20. 20.
    Brook I: Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis 1985, 4:491–495.PubMedCrossRefGoogle Scholar
  21. 21.
    Adams EM, Gudmundsson S, Yocum DE, et al.: Streptococcal myositis. Arch Intern Med 1985, 145:1020–1023.PubMedCrossRefGoogle Scholar
  22. 22.
    Stevens DL: Invasive group A streptococcus infections. Clin Infect Dis 1992, 14:2–13.PubMedGoogle Scholar
  23. 23.
    Martin PR, Hoiby EA: Streptococcal serogroup A epidemic in Norway 1987–1988. Scand J Infect Dis 1990, 22:421–429.PubMedGoogle Scholar
  24. 24.
    Kohler W: Streptococcal toxic shock syndrome. Zentralbl Bakteriol 1990, 272:257–264.PubMedGoogle Scholar
  25. 25.
    Hribalova V: Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988, 108:772.PubMedGoogle Scholar
  26. 26.
    Gaworzewska ET, Coleman G: Correspondence: group A streptococcal infections and a toxic shock-like syndrome. N Engl J Med 1989, 321:1546.Google Scholar
  27. 27.
    Eagle H: Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952, 13:389–399.PubMedCrossRefGoogle Scholar
  28. 28.
    Stevens DL, Bryant-Gibbons AE, Bergstrom R, Winn V: The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23–28.PubMedGoogle Scholar
  29. 29.
    Stevens DL, Bryant AE, Yan S: Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 1994, 4:297–301.CrossRefPubMedGoogle Scholar
  30. 30.
    Stevens DL, Yan S, Bryant AE: Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401–1405.PubMedGoogle Scholar
  31. 31.
    Yan S, Mendelman PM, Stevens DL: The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett 1993, 110:313–318.PubMedCrossRefGoogle Scholar
  32. 32.
    Yan S, Bohach GA, Stevens DL: Persistent acylation of highmolecular weight penicillin binding proteins by penicillin induces the post antibiotic effect in Streptococcus pyogenes. J Infect Dis 1994, 170:609–614.PubMedGoogle Scholar
  33. 33.
    Stevens DL, Maier KA, Mitten JE: Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987, 31:213–218.PubMedGoogle Scholar
  34. 34.
    Gemmell CG, Peterson PK, Schmeling D, et al.: Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981, 67:1249–1256.PubMedCrossRefGoogle Scholar
  35. 35.
    Stevens DL, Bryant AE, Hackett SP: Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995, 20:S154-S157.PubMedGoogle Scholar
  36. 36.
    Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999, 18:1096–1100.PubMedCrossRefGoogle Scholar
  37. 37.
    Stevens DL, Madaras-Kelly KJ, Richards DM: In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes. Antimicrob Agents Chemother 1998, 42:1266–1268.PubMedGoogle Scholar
  38. 38.
    Cruz K, Hollenberg S: Update on septic shock: the latest approaches to treatment. J Crit Illn 2003, 18:162–168. This is a current, concise review regarding the management of septic shock in patients in the intensive care unit.Google Scholar
  39. 39.
    Fisher CJ, Horowitz BZ, Albertson TE: Cardiorespiratory failure in toxic shock syndrome: effect of dobutamine. Crit Care Med 1985, 13:160–165.PubMedCrossRefGoogle Scholar
  40. 40.
    Kaul R, McGeer A, Norrby-Teglund A, et al.: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. Clin Infect Dis 1999, 28:800–807.PubMedGoogle Scholar
  41. 41.
    Barry W, Hudgins L, Donta S, Pesanti E: Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992, 267:3315–3316.PubMedCrossRefGoogle Scholar
  42. 42.
    Yong JM: Necrotising fasciitis. Lancet 1994, 343:1427.PubMedCrossRefGoogle Scholar
  43. 43.
    Sriskandan S, Moyes D, Buttery LK, et al.: Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes. J Infect Dis 1996, 173:1399–1407.PubMedGoogle Scholar
  44. 44.
    Miwa K, Fukuyama M, Ida N, et al.: Preparation of a superantigen-adsorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 2003, 7:21–28. The authors of this paper developed a polystyrene-based device that absorbed more than 70% of staphylococcal and streptococcal superantigens from human plasma and reduced the available levels of TNF-_ and interleukin-8 from superantigen-stimulated whole blood. Extracorporeal blood purification through this device in superantigen-treated animals resulted in significant improvement in survival.PubMedCrossRefGoogle Scholar
  45. 45.
    Stevens DL, Bryant AE, Hackett SP, et al.: Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. J Infect Dis 1996, 173:619–626.PubMedGoogle Scholar
  46. 46.
    Schwartz B, Elliot JA, Butler JC, et al.: Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992, 15:277–284.PubMedGoogle Scholar
  47. 47.
    Valenzuela TD, Hooton TM, Kaplan EL, Schlievert PM: Transmission of ’toxic strep’ syndrome from an infected child to a firefighter during CPR. Ann Emerg Med 1991, 20:90–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Stamm WE, Feeley JC, Facklam RR: Wound infections due to group A streptococcus traced to a vaginal carrier. J Infect Dis 1978, 138:287–292.PubMedGoogle Scholar
  49. 49.
    Davies HD, McGeer A, Schwartz B, et al.: Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996, 335:547–554.PubMedCrossRefGoogle Scholar
  50. 50.
    Prevention of invasive group A streptococcal diseases among household contacts of case-patients: is prophylaxis warranted? The Working Group on Prevention of Invasive Group A Streptococcal Infections. JAMA 1998, 279:1206–1210.Google Scholar
  51. 51.
    Liu VC, Stevenson JG, Smith AL: Group A streptococcus mural endocarditis. Pediatr Infect Dis J 1992, 11:1060–1062.PubMedCrossRefGoogle Scholar
  52. 52.
    Batzloff MR, Hayman WA, Davies MR, et al.: Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003, 187:1598–1608. This paper represents a novel approach to vaccine development. A 12-amino acid peptide from the C-repeat (ie, conserved) region of M protein was conjugated to diphtheria toxin. Active immunization elicited opsonic antibody against several different M-types and was protective against challenge with an M-6 strain of GAS.PubMedCrossRefGoogle Scholar
  53. 53.
    Guzman CA, Talay SR, Molinari G, et al.: Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999, 179:901–906.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2003

Authors and Affiliations

  • Dennis L. Stevens
    • 1
  1. 1.Infectious Diseases SectionVeterans Affairs Medical CenterBoiseUSA

Personalised recommendations